These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15133630)

  • 1. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
    Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
    Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17.
    Bruserud O; von Volkman HL; Ulvestad E
    Acta Haematol; 2000; 104(2-3):80-91. PubMed ID: 11154979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
    Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
    Scand J Immunol; 1998 Jan; 47(1):54-62. PubMed ID: 9467659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
    Ersvaer E; Liseth K; Skavland J; Gjertsen BT; Bruserud Ø
    BMC Immunol; 2010 Jul; 11():38. PubMed ID: 20618967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
    Bruserud O
    Int J Immunopharmacol; 2000 Jan; 22(1):69-81. PubMed ID: 10684990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia.
    Bruserud O; Ulvestad E
    J Interferon Cytokine Res; 2000 Nov; 20(11):947-54. PubMed ID: 11096451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes.
    Wendelbo Ø; Glenjen N; Bruserud Ø
    J Interferon Cytokine Res; 2002 Oct; 22(10):1057-65. PubMed ID: 12433286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
    Bruserud O
    Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia.
    Guo W; Xing C; Dong A; Lin X; Lin Y; Zhu B; He M; Yao R
    Cancer Biol Ther; 2013 Oct; 14(10):916-21. PubMed ID: 24030391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
    Bruserud O; Ulvestad E
    Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.
    Ersvaer E; Hampson P; Hatfield K; Ulvestad E; Wendelbo Ø; Lord JM; Gjertsen BT; Bruserud Ø
    Cancer Immunol Immunother; 2007 Jun; 56(6):913-25. PubMed ID: 17115221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia.
    Bruserud O
    Int Immunopharmacol; 2001 Nov; 1(12):2183-95. PubMed ID: 11710547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia.
    Bruserud O; Ulvestad E; Halstensen A; Berentsen S; Bergheim J; Nesthus I
    Eur J Haematol; 1997 Nov; 59(5):269-76. PubMed ID: 9414637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
    Bruserud Ø; Wendelboe Ø
    Expert Opin Biol Ther; 2001 Nov; 1(6):1005-16. PubMed ID: 11728232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.
    Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ
    Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.
    Wendelbo Ø; Bruserud Ø
    J Hematother Stem Cell Res; 2003 Oct; 12(5):525-35. PubMed ID: 14594509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.
    Ersvaer E; Hampson P; Wendelbo Ø; Lord JM; Gjertsen BT; Bruserud Ø
    Hematology; 2007 Jun; 12(3):199-207. PubMed ID: 17558695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of short-course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia.
    Cetin M; Hiçsönmez G; Tuncer AM; Kansu E; Canpynar H
    Exp Hematol; 1996 Aug; 24(10):1191-4. PubMed ID: 8765493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Dysfunction After Completion of Childhood Leukemia Therapy.
    Perkins JL; Harris A; Pozos TC
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):1-5. PubMed ID: 27820131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.